glp-1 drug made by eli lilly to seek approval of new weight-loss this year Eli Lilly's GLP-1 pill that

Patients on GLP-1 drugs showed improvement in heart health measures like A1C (a marker for diabetes) and blood pressure

Pharmaceutical companies have been trying to produce small-molecule GLP-1 agonists that are shelf-stable and can be taken orallyfor instance, Pfizer and Eli Lilly have developed Danuglipron and Orforglipron, respectivelybut we know very little about how they work, said Ali Gler, a neuroscientist at the University of Virginia

This could enable a higher-margin product line

What they're saying: "The sheer cost of these medications is a huge barrier to access," Dr

Mechanistic Comparison# Dosing Comparison# Amycretin Dosing# Amycretin dosing is investigational: Subcutaneous: Once-weekly injection, doses up to 60 mg studied in phase 1b/2a over 36 weeks Oral: Daily tablet, doses up to 50 mg (or 2 x 50 mg) studied in phase 1 Phase 2 T2D: Both subcutaneous and oral formulations studied over 36 weeks Phase 3 dose selection will be informed by the completed phase 2 data

Combination therapy with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes: A real-world evidence study